Prenatal medication exposure and epigenetic outcomes: a systematic literature review and recommendations for prenatal pharmacoepigenetic studies

Epigenetics. 2022 Apr;17(4):357-380. doi: 10.1080/15592294.2021.1903376. Epub 2021 Apr 29.

Abstract

When used during pregnancy, analgesics and psychotropics pass the placenta to enter the foetal circulation and may induce epigenetic modifications. Where such modifications occur and whether they disrupt normal foetal developme nt, are currently unanswered questions. This field of prenatal pharmacoepigenetics has received increasing attention, with several studies reporting associations between in utero medication exposure and offspring epigenetic outcomes. Nevertheless, no recent systematic review of the literature is available. Therefore, the objectives of this review were to (i) provide an overview of the literature on the association of prenatal exposure to psychotropics a nd analgesics with epigenetic outcomes, and (ii) suggest recommendations for future studies within prenatal pharmacoepigenetics. We performed systematic literature searches in five databases. The eligible studies assessed human prenatal exposure to psychotropics or analgesics, with epigenetic analyses of offspring tissue as an outcome. We identified 18 eligible studies including 4,419 neonates exposed to either antidepressants, antiepileptic drugs, paracetamol, acetylsalicylic acid, or methadone. The epigenetic outcome in all studies was DNA methylation in cord blood, placental tissue or buccal cells. Although most studies found significant differences in DNA methylation upon medication exposure, almost no differences were persistent across studies for similar medications and sequencing methods. The reviewed studies were challenging to compare due to poor transparency in reporting, and heterogeneous methodology, design, genome coverage, and statistical modelling. We propose 10 recommendations for future prenatal pharmacoepigenetic studies considering both epidemiological and epigenetic perspectives. These recommendations may improve the quality, comparability, and clinical relevance of such studies. PROSPERO registration ID: CRD42020166675.

Keywords: DNA methylation; EWAS; Epigenetics; analgesics; epidemiology; epigenetic epidemiology; literature review; prenatal exposure; psychotropics; recommendations.

Publication types

  • Systematic Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • DNA Methylation*
  • Epigenesis, Genetic
  • Epigenomics
  • Female
  • Humans
  • Infant, Newborn
  • Mouth Mucosa
  • Placenta
  • Pregnancy
  • Prenatal Exposure Delayed Effects* / genetics

Grants and funding

This work was supported by the PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway and the European Research Council (ERC) Starting Grant “DrugsInPregnancy” [grant number: 678033].